Corcept Therapeutics Files Second Quarter 10-Q With SEC
The biopharmaceutical company submitted its quarterly financial disclosure as recent insider transactions show executive options activity.
Quarterly Filing Submitted
Corcept Therapeutics Incorporated filed its quarterly report on Form 10-Q with the Securities and Exchange Commission on July 29, according to SEC EDGAR filings. The Menlo Park, California-based biopharmaceutical company, which specializes in treatments for serious metabolic diseases caused by excess cortisol, submitted the standard disclosure covering its second quarter 2026 financial performance.
The company carries a market capitalization of approximately $12 billion, with shares last closing at $114.49.
Recent Insider Activity
MarginX data shows notable insider transactions in recent weeks. Atabak Mokari, a company executive, exercised stock options on two separate occasions—acquiring 24,167 shares in one transaction and 15,833 shares in another. Mokari subsequently sold 28,460 shares, according to regulatory filings tracked by MarginX.
While options exercises and sales are routine activities that can occur for various personal financial planning reasons, the transactions provide transparency into executive equity compensation activity at the biopharmaceutical firm.
Looking Ahead
Investors will have several key dates to monitor in the coming months. The Federal Reserve is scheduled to announce its next interest rate decision along with updated economic projections on September 16, followed by another FOMC decision on October 28. These macroeconomic events could influence broader market conditions for healthcare and biotechnology stocks.
Corcept Therapeutics is expected to report its third quarter 2026 financial results on November 4, according to MarginX data. That earnings report will provide investors with updated guidance and performance metrics approximately three months from the period covered in this 10-Q filing.
The 10-Q filing is a mandatory quarterly disclosure that provides a comprehensive overview of a company's financial position, including unaudited financial statements, management discussion and analysis, and disclosures about market risk and internal controls.
This article was generated by MarginX from public news on 2026-07-29. It is not investment advice.